Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Factors Associated with Subsequent Cerebral Vascular Disease after Emergency Department Headache Visits: a nested case-control study
Headache
P16 - Poster Session 16 (5:30 PM-6:30 PM)
7-008

To identify factors associated with hospitalization for cerebrovascular disease (CVD) after an Emergency Department (ED) discharge with a diagnosis of primary headache.

When patients discharged from the ED with a primary headache diagnosis return with CVD this may represent a preventable medical error.  

We conducted a retrospective nested case-control study using a cohort of headache patients seen in 1 of 4 EDs from 9/1/2013 to 9/1/2018.  Eligible patients were discharged home with a diagnosis of primary headache. Within 365 days of ED discharge, cases had a subsequent hospitalization for CVD, while controls did not. Controls were matched to cases based on date of ED arrival and ED facility. Covariates were abstracted by chart review and all CVD outcomes were confirmed by a board-certified vascular neurologist. We used standard tests of comparison to compare cases to controls setting an alpha <0.05.

A total of 224 patients were included in our study; 112 cases and 112 controls. In both groups, 67% (n=75) of patients were female and most were English speaking (71.4% vs. 75%, p=0.65). On average, cases were older than controls (63.5 SD: 15.9 vs. 41.7 SD: 14.8, p=0.001) and were more likely to be Black or African American (39.3% vs. 25.9%, p=0.05). Additional variables including presenting symptoms, vascular comorbidities, headache features, and medications are being assessed.  

Patients discharged from the ED with a primary headache diagnosis and subsequently hospitalized for CVD are older and more often Black or African American than those without subsequent CVD hospitalization. Factors associated with misdiagnosis (minority race) and CVD risk (advanced age) are associated with subsequent CVD hospitalization; addition data collection is ongoing to improve risk stratification. Awareness of these factors may improve the detection of CVD in patients presenting with headache.

Authors/Disclosures
Jenny L. Rotblat, MD (New York-Presbyterian Hospital)
PRESENTER
Ms. Lu has nothing to disclose.
Richard B. Lipton, MD, FÂé¶¹´«Ã½Ó³»­ (Albert Einstein College of Medicine) Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.
No disclosure on file
Daniel L. Labovitz, MD An immediate family member of Dr. Labovitz has received personal compensation for serving as an employee of Herrick Feinstein.
Ava L. Liberman, MD (Weill Cornell Medicine) Dr. Liberman has nothing to disclose.